INT81989

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 7.57
Pain Relevance 2.40

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Tnfsf11) extracellular space (Tnfsf11) extracellular region (Tnfsf11)
plasma membrane (Tnfsf11) intracellular (Tnfsf11) response to stress (Tnfsf11)
Anatomy Link Frequency
osteoclast 2
joint 1
osteoblasts 1
synovial cells 1
Tnfsf11 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Arthritis 290 98.68 Very High Very High Very High
spinal inflammation 14 98.64 Very High Very High Very High
rheumatoid arthritis 42 98.58 Very High Very High Very High
metalloproteinase 2 98.26 Very High Very High Very High
COX2 2 98.04 Very High Very High Very High
cytokine 31 90.88 High High
cINOD 8 82.48 Quite High
COX-2 inhibitor 4 76.48 Quite High
Inflammation 61 60.60 Quite High
imagery 30 30.16 Quite Low
Disease Link Frequency Relevance Heat
Seronegative Spondarthritis 136 98.68 Very High Very High Very High
Low Back Pain 17 98.64 Very High Very High Very High
Rheumatoid Arthritis 46 98.58 Very High Very High Very High
Osteoporosis 98 98.32 Very High Very High Very High
Hypercalcemia 22 95.84 Very High Very High Very High
Disease 79 95.80 Very High Very High Very High
Experimental Arthritis 8 92.64 High High
Arthritis 162 90.16 High High
Osteolysis 18 88.56 High High
Bone Cancer 25 87.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, our study is the first to report that HEP extract stimulated the expression of OPG mRNA but suppressed the expression of RANKL mRNA in the UMR 106 cell line, resulting in a dose-dependent increase in the OPG/RANKL ratio.
Positive_regulation (increase) of RANKL
1) Confidence 0.54 Published 2005 Journal Evidence-based Complementary and Alternative Medicine Section Body Doc Link PMC1193542 Disease Relevance 0.25 Pain Relevance 0
Myeloma cells upregulate RANKL and downregulate osteoprotegerin, resulting in increased osteoclastic activity.
Positive_regulation (upregulate) of RANKL associated with osteoporosis
2) Confidence 0.44 Published 2010 Journal Advances in Hematology Section Body Doc Link PMC2905716 Disease Relevance 1.03 Pain Relevance 0.05
B ligand (RANKL) mRNA expression, resulting in a dose-dependent increase in OPG/RANKL mRNA ratio (P < 0.01 versus vehicle-treated).
Positive_regulation (increase) of RANKL mRNA
3) Confidence 0.42 Published 2005 Journal Evidence-based Complementary and Alternative Medicine Section Abstract Doc Link PMC1193542 Disease Relevance 0.22 Pain Relevance 0
As shown in Fig. 5C, the OPG/RANKL ratio in UMR 106 cells increased when they were treated with HEP extract at 100 ?
Positive_regulation (increased) of RANKL
4) Confidence 0.18 Published 2005 Journal Evidence-based Complementary and Alternative Medicine Section Body Doc Link PMC1193542 Disease Relevance 0.34 Pain Relevance 0
IL-17 also induces the expression of matrix metalloproteinase-1 and -13 in RA synovial cells and osteoblasts [15,16], and induces the expression of RANKL (receptor activator of nuclear factor-?
Positive_regulation (activator) of RANKL in osteoblasts associated with rheumatoid arthritis and metalloproteinase
5) Confidence 0.17 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656239 Disease Relevance 1.44 Pain Relevance 0.59
IL-17 also induces the expression of matrix metalloproteinase-1 and -13 in RA synovial cells and osteoblasts [15,16], and induces the expression of RANKL (receptor activator of nuclear factor-?
Positive_regulation (activator) of RANKL in synovial cells associated with rheumatoid arthritis and metalloproteinase
6) Confidence 0.06 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656239 Disease Relevance 1.44 Pain Relevance 0.59
Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2.
Positive_regulation (upregulation) of osteoclast differentiation factor in osteoclast associated with cox2
7) Confidence 0.06 Published 1999 Journal Biochem. Biophys. Res. Commun. Section Title Doc Link 10334922 Disease Relevance 0.27 Pain Relevance 0.13
The soluble factors analyzed in this study are key regulators of bone turnover, and our data suggest that systemic expression of factors promoting osteoclastogenesis and bone loss (Dkk-1, M-CSF, RANKL) is disordered in patients with PsA.
Positive_regulation (promoting) of RANKL associated with arthritis
8) Confidence 0.05 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945067 Disease Relevance 0.73 Pain Relevance 0.29
Our data indicate that the extent of bone loss at the peripheral joint is associated with elevated circulating M-CSF and RANKL concentrations, but that these factors are not associated with the extent of systemic bone loss in PsA.
Positive_regulation (elevated) of RANKL in joint associated with arthritis
9) Confidence 0.05 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945067 Disease Relevance 0.77 Pain Relevance 0.27
Moreover, Northern blot analysis revealed that the level of osteoclast differentiation factor (ODF) mRNA increased by treatment with BMP-2 and IL-1alpha in osteoblast-like cells.
Positive_regulation (increased) of osteoclast differentiation factor in osteoclast associated with osteoporosis
10) Confidence 0.04 Published 1999 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 10334922 Disease Relevance 0.49 Pain Relevance 0.12
Serum sRANKL levels and sRANKL/OPG ratios are up-regulated in patients with AS and have relationship with BMD and radiological changes.
Positive_regulation (up-regulated) of sRANKL
11) Confidence 0.01 Published 2006 Journal Rheumatology (Oxford) Section Body Doc Link 16567356 Disease Relevance 0.15 Pain Relevance 0
OBJECTIVE: To assess bone mineral density (BMD), serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and osteoprotegerin (OPG) in patients with ankylosing spondylitis (AS), and to determine their relationships with disease activities.
Positive_regulation (activator) of sRANKL associated with spinal inflammation and disease
12) Confidence 0.01 Published 2006 Journal Rheumatology (Oxford) Section Abstract Doc Link 16567356 Disease Relevance 0.44 Pain Relevance 0.35

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox